EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma

Krzysztof Jamroziak, Dominik Dytfeld, Tadeusz Kubicki, Magdalena Dutka, Tomasz Wróbel, Krzysztof Giannopoulos, Agnieszka Końska, Agnieszka Druzd-Sitek, Agata Tyczyńska, Magdalena Olszewska-Szopa, Marta Morawska, Agnieszka Szeremet und 10 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70373 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Krzysztof Jamroziak und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Antineoplastic Agents, Watchful Waiting. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Janssen Pharmaceuticals, Janssen Pharmaceutica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The progression pattern of multiple myeloma is heterogeneous and often characterised by asymptomatic biochemical progression preceding the onset of organ‐related symptoms. It is unknown whether pre‐emptive treatment of biochemical progression can affect long‐term outcomes. The PREDATOR‐BR trial is a randomised, multicentre study that enrolled 92 patients who met criteria for biochemical progression but not the criteria for significant paraprotein relapse (SPR). The participants were assigned to either daratumumab monotherapy or observation. The primary end‐point was event‐free survival (EFS), defined as the time until clinical relapse, SPR or death from any cause. At the prespecified interim analysis with a median follow‐up time of 16.7 months, the median EFS was 28.9 months with daratumumab and 4.0 months in the observation arm (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.14–0.43). The response rate was 61.0% in the treatment arm and 6.8% in the observation arm ( p < 0.0001). The 24‐month overall survival was 100% in the treatment group and 70.5% in the observation group (HR, 0.04; 95% CI, 0.00–0.34). Treatment was associated with manageable safety and no deterioration in quality of life. These results suggest that early treatment initiation during asymptomatic biochemical relapse of multiple myeloma may delay clinical relapse and prolong patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, MonoclonalAntineoplastic AgentsWatchful WaitingHumansFemaleMaleAgedMiddle AgedRecurrenceDisease ProgressionAged, 80 and over

Stichwörter der Autor:innen

daratumumabmultiple myelomapre‐emptive treatment

Substanzen

daratumumabAntibodies, MonoclonalAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
  • Department of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
  • Department of Haematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
  • Department and Clinic of Haematology, Cellular Therapies and Internal Medicine, Wrocław Medical University, Wrocław, Poland.
  • Department of Experimental Haematooncology, Medical University in Lublin, Lublin, Poland.
  • Department of Haematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland.

ORCID-Profile: Anna Kopinska, Jan Maciej Zaucha, Bartosz Puła

Förderung

  • Janssen Pharmaceuticals
  • Janssen Pharmaceutica

Zitieren

APA

Jamroziak, K., Dytfeld, D., Kubicki, T., Dutka, M., Wróbel, T., Giannopoulos, K., Końska, A., Druzd-Sitek, A., Tyczyńska, A., Olszewska-Szopa, M., Morawska, M., Szeremet, A., Kopinska, A., Wiśniewski, K., Czyż, J., Helbig, G., Gil, L., Zaucha, J. M., Kruk-Kwapisz, D., …, & Puła, B. (2026). Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/bjh.70373

Vancouver

Jamroziak K, Dytfeld D, Kubicki T, Dutka M, Wróbel T, Giannopoulos K, et al. Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma. British Journal of Haematology. 2026. doi:10.1111/bjh.70373

BibTeX
@article{Jamroziak2026,
  author = {Jamroziak, Krzysztof and Dytfeld, Dominik and Kubicki, Tadeusz and Dutka, Magdalena and Wróbel, Tomasz and Giannopoulos, Krzysztof and Końska, Agnieszka and Druzd-Sitek, Agnieszka and Tyczyńska, Agata and Olszewska-Szopa, Magdalena and Morawska, Marta and Szeremet, Agnieszka and Kopinska, Anna and Wiśniewski, Kamil and Czyż, Jarosław and Helbig, Grzegorz and Gil, Lidia and Zaucha, Jan Maciej and Kruk-Kwapisz, Dorota and Walewski, Jan and Górecki, Tomasz and Puła, Bartosz},
  title = {Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70373}
}
Kostenlos starten →